Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, and other carcinomas. The Company leverages its proprietary technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with metastatic cancer involving the central nervous system (CNS). Biocept’s patented CNSide™ technology platform captures and analyzes tumor-associated molecular markers in both cerebrospinal fluid (CSF) tumor cells (CSF-TCs) and in cell-free DNA (cfDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options.
There are no items to display.